Argent Biopharma (LSE:RGT) Tax Provision : £0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Argent Biopharma Tax Provision?

Argent Biopharma's tax provision for the six months ended in Dec. 2024 was £0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was £0.00 Mil.

Argent Biopharma Tax Provision Historical Data

The historical data trend for Argent Biopharma's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma Tax Provision Chart

Argent Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Tax Provision

Get a 7-Day Free Trial

0.02

Argent Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Argent Biopharma Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Argent Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (LSE:RGT) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

RGTLF:USA H5O0:Germany RGT:Australia

Address

295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008

Website

https://www.argentbiopharma.com

Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.